Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutated Melanoma”

130 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 130 results

Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Testing effectiveness (Phase 2)Ended earlyNCT01942993
What this trial is testing

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Who this might be right for
Melanoma
Philip Friedlander 3
Early research (Phase 1)Ended earlyNCT05388877
What this trial is testing

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the Central Nervous System+1 more
Mayo Clinic 13
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Early research (Phase 1)Study completedNCT01596140
What this trial is testing

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Who this might be right for
Advanced CancerSolid Tumor
M.D. Anderson Cancer Center 27
Not applicableStudy completedNCT06557291
What this trial is testing

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

Who this might be right for
BRAF V600 Mutated-Stage III/IV Melanoma
Novartis 38
Early research (Phase 1)Study completedNCT01954043
What this trial is testing

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Who this might be right for
Cancer
GlaxoSmithKline 23
Early research (Phase 1)Temporarily pausedNCT01841463
What this trial is testing

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Who this might be right for
Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Piramal Enterprises Limited 100
Not applicableStudy completedNCT01744860
What this trial is testing

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 420
Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Early research (Phase 1)Looking for participantsNCT07244835
What this trial is testing

DEG6498 in Participants With Solid Tumors

Who this might be right for
Malignant Neoplasms
Degron Therapeutics Co. 100
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Early research (Phase 1)Study completedNCT01673737
What this trial is testing

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Who this might be right for
Neoplasm Malignant
Sanofi 75
Large-scale testing (Phase 3)Looking for participantsNCT07440290
What this trial is testing

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+17 more
Cancer Research UK 30
Next Page